EP11.03-16 Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody

Autor: Imakita, T., Fujita, K., Ito, T., Saito, Z., Oi, I., Kanai, O., Tachibana, H., Mio, T.
Zdroj: In Journal of Thoracic Oncology November 2023 18(11) Supplement:S627-S627
Databáze: ScienceDirect